Euclidean Capital related stories
All articles and analysis
Leal Therapeutics inks $30m Series ASV Health Investors' Dementia Discovery Fund led the round.
- Redesign Health collects $175m for new fund
Investors include Declaration Partners, Euclidean Capital and True North Advisors.
- VC-backed Stablix appoints Saiah as CSO
Most recently, he was CSO at Navitor Pharmaceuticals.
VC-backed Stablix recruits Kingsley as CEOMost recently, he was president and CEO of Scholar Rock.
April procures $10m seedApril, a tax platform, has raised $10 million in seed funding.
- Duality Technologies lands $30m Series B
Duality Technologies, a provider of privacy-enhanced data collaboration solutions, has secured $30 million in Series B funding.
- ASAPP picks up $120m Series C
ASAPP Inc, an artificial intelligence research-driven company, has raised $120 million in Series C financing.
- A2 Biotherapeutics scores $71.5m Series B
Agoura Hills, California-based A2 Biotherapeutics, a developer of cell therapies for solid tumor cancer patients, has raised $71.5 million in Series B financing.
- Nura Bio reels in $73m Series A
South San Francisco-based Nura Bio Inc, a biopharma company focused on developing neuroprotective drugs, has raised $73 million in Series A funding.
Enterprise tech funding in NY remains robust, driven by megadealsMore than $2.7bn has been invested across 95 deals in 2020 so far, up 29% from the $1.9bn across 52 deals in the first half of 2019.